A Synthetic Cyclized Antimicrobial Peptide with Potent Effects against Drug-Resistant Skin Pathogens

Area of Science:

• Microbiology
• Dermatology
• Peptide Therapeutics

Background:

• Conventional antibiotics face increasing bacterial resistance, necessitating novel therapeutic strategies for dermal infections.
• The human host defense peptide LL-37 serves as a basis for developing new antimicrobial agents.

Purpose of the Study:

• To evaluate the efficacy of a designed antimicrobial peptide, CD4-PP, against common skin pathogens, including antibiotic-resistant strains.
• To investigate the immunomodulatory effects of CD4-PP on keratinocytes and its therapeutic potential in infected skin models.

Main Methods:

• Design and synthesis of a backbone-cyclized antimicrobial peptide, CD4-PP, derived from LL-37.
• Assessment of CD4-PP's direct antibacterial activity against sensitive and resistant bacterial strains and clinical isolates.
• Evaluation of CD4-PP's impact on innate immunity in keratinocytes and its effectiveness in clearing bacterial infections in vitro.
• Testing CD4-PP's wound healing capabilities in a keratinocyte model infected with Methicillin-resistant Staphylococcus aureus (MRSA).

Main Results:

• CD4-PP demonstrated potent antibacterial effects against common skin pathogens, including antibiotic-resistant strains, at low micromolar concentrations (<2 μM).
• CD4-PP modulated innate immune responses in keratinocytes and successfully cleared bacterial infections within these cells.
• Treatment with CD4-PP significantly reduced the wound area in an MRSA-infected keratinocyte model.

Conclusions:

• The backbone-cyclized antimicrobial peptide CD4-PP exhibits significant direct antibacterial activity and immunomodulatory properties.
• CD4-PP shows potential as a future therapeutic agent for treating skin infections caused by antibiotic-resistant bacteria, including MRSA.
• CD4-PP represents a promising alternative to conventional antibiotics for managing challenging dermal infections.